According to our new research study on "Epilepsy Market Forecast to 2030 - Global Analysis - by Type, Route of Administration, Treatment Type, Age Group, Distribution Channel, and Geography," the market is expected to grow from US$ 7.7 billion in 2022 to US$ 10.7 billion by 2030; it is estimated to record a CAGR of 4.1% from 2022-2030. Key factors driving the growth of the epilepsy market are the rising prevalence of epilepsy and increasing investments in the development of epilepsy therapies. However, the recall of products hinders the growth of the market.
Gene therapies are being explored as potential treatment options for certain genetic epilepsies. This innovative approach is aimed at treating diseases by modifying or manipulating the genetic makeup of cells. The fundamental principle of gene therapy is to correct or replace faulty genes that contribute to the development or progression of a particular condition. Since epileptic seizures are caused by excessive brain cell activity (neurons) in particular parts of the organ, targeting these neurons and turning them off could help prevent seizures. Two standard gene therapy techniques that can be employed to design an epilepsy treatment are gene addition and gene editing. Gene addition involves adding genetic material to an individual's cells to balance a missing or abnormal gene, while gene editing involves treating genetic epilepsy by directly modifying an individual's gene. By targeting specific genes associated with epilepsy and manipulating cellular genetic material, gene therapy can help restore normal cellular function and inhibit seizure generation.
Examining the genetic causes of a condition allows healthcare providers to offer more personalized and targeted treatment approaches. In cases involving heritable mutations, this knowledge aids in understanding the risks for affected families and facilitates genetic counseling, followed by informed decision-making. Ongoing advancements in the identification of genetic factors causing epilepsy to play a crucial role in guiding the medical care and management of affected individuals. Next-generation sequencing has largely driven significant progress in the field of genetics. This high-throughput genetic sequencing technique enables a faster and more comprehensive analysis of DNA, thereby aiding the identification of genetic causes of conditions such as epilepsy.
The continued progress in genetic research holds the potential to improve the care and support provided to individuals with epilepsy and their families. By targeting genes associated with ion channels, neurotransmitter receptors, or cellular signaling pathways, researchers can investigate how alterations in these genes contribute to epileptogenesis.
Although gene therapy for epilepsy is still in the early stages of development, preclinical studies in animal models have shown promising results. Animal models with specific epilepsy-related genetic mutations have been treated using gene therapy approaches, resulting in reduced seizure frequency and improved seizure control. In December 2023, UCL Queen Square Institute of Neurology researchers developed a new gene therapy to cure a devastating form of childhood epilepsy, which has been shown to notably reduce seizures in mice. They assessed a gene therapy based on the overexpression of a potassium channel that controls neuronal excitability in a mouse model with focal cortical dysplasia in the frontal lobe. The researchers injected an engineered potassium channel gene termed EKC into the affected frontal lobe of epileptic mice. They employed a virus lacking replicability as a vector to carry the potassium channel gene. The researchers found that gene therapy lowered seizures by an average of 87% compared to the control group without altering the mouse's memory or behavior. Taking into account the unmet needs in epilepsy therapeutics, it can be utilized to treat children who are severely affected by uncontrolled seizures.
Many gene therapy trials for the treatment of epilepsy are currently underway or in the planning stages. The purpose of these trials is to estimate the safety and effectiveness of gene therapies in human patients with specific genetic forms of epilepsy. CombiGene's CG01 is an appropriate drug candidate for treating epilepsy. It is an AAV-based gene therapy that has the potential to enhance the quality of life for people with drug-resistant focal epilepsy, for which no effective treatment is available currently. The therapy candidate CG01 uses a gene therapy vector to deliver a combination of neuropeptide Y and its receptor Y2 directly to the area of the brain that triggers epileptic seizures.
Thus, gene therapy is likely to serve as a promising new trend in the epilepsy market in the coming years.
Based on distribution channel, the epilepsy market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest epilepsy market share in 2022. Hospital pharmacies are an essential aspect of patient care at a healthcare facility. Pharmaceuticals are purchased, stored, compounded, dispensed, manufactured, tested, packaged, and distributed in these departments in hospitals. Controlling the use of pharmaceuticals in hospitals and other medical facilities is the primary responsibility of hospital pharmacies. They aim to improve patient outcomes through the selection, prescription, procurement, delivery, administration, and review of pharmaceuticals.
Hospital pharmacies purchase pharmaceuticals from different companies and supply them for outpatient or inpatient treatments. They usually offer therapeutic and critical care drugs that have cardiology, neurology, urology, pathology, hematology, and dermatology applications. These pharmacies maintain stocks of epilepsy drugs to ensure their ready availability for patients. Thus, the hospital pharmacies segment accounts for a considerable size of the epilepsy market.
In addition, the retail pharmacies segment is expected to register the highest CAGR in the epilepsy market during 2022-2030. Retail pharmacy stores sell prescription drugs, over-the-counter drugs, and some fast-moving consumer goods, along with providing related services. Modern retail pharmacy chains are digitized, organized, and tech-enabled, which allows them to track medication inventories and sell 100% reliable goods. In addition, retail pharmacy chains provide value-added services for consumers opting for medical claims or insurance filings. They can also be requested to refurbish previous bills or memos. Moreover, their locations make them accessible for patients to fill their prescriptions and receive counseling from pharmacists.
Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, CombiGene AB, Livanova PLC, Novartis AG, Medtronic PLC, GSK PLC, and H. Lundbeck AS are among the leading companies profiled in the epilepsy market report.
Epilepsy Market, by Region, 2022(%)
Source: The Insight Partners Analysis
Based on type, the epilepsy market is categorized into progressive myoclonic epilepsy, generalized epilepsy, reflex epilepsy, and others. In terms of route of administration, the market is classified into oral, parenteral, and others. The market, by treatment type, is segmented into first-generation drugs, second-generation drugs, and third-generation drugs. In terms of age group, the epilepsy market is bifurcated into adults and children. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and others. Based on geography, the epilepsy market is categorized into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com